July 2, 2020 / 12:43 PM / a month ago

BRIEF-Apellis Completes Enrollment In Phase 3 Study Of Pegcetacoplan

July 2 (Reuters) - Apellis Pharmaceuticals Inc:

* APELLIS COMPLETES ENROLLMENT IN PHASE 3 STUDY OF PEGCETACOPLAN IN TREATMENT-NAÏVE PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)

* APELLIS PHARMACEUTICALS INC - PLANS TO SUBMIT MARKETING APPLICATIONS FOR PEGCETACOPLAN FOR TREATMENT OF PNH BOTH IN U.S., EU IN H2 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below